Get the Stockscreener App
114.48
3.57%
-4.24
After Hours:
114.48
Neurocrine Biosciences Inc stock is traded at $114.48, with a volume of 1.37M.
It is down -3.57% in the last 24 hours and down -23.73% over the past month.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
See More
Previous Close:
$118.72
Open:
$118.65
24h Volume:
1.37M
Relative Volume:
1.20
Market Cap:
$11.70B
Revenue:
$2.24B
Net Income/Loss:
$385.90M
P/E Ratio:
30.69
EPS:
3.73
Net Cash Flow:
$440.10M
1W Performance:
-3.89%
1M Performance:
-23.73%
6M Performance:
-8.49%
1Y Performance:
-12.81%
1-Day Range:
$114.29
$119.00
1-Week Range:
$114.29
$120.00
52-Week Range:
$110.95
$157.98
Neurocrine Biosciences Inc Stock (NBIX) Company Profile
Name
Neurocrine Biosciences Inc
Sector
Phone
(858) 617-7600
Address
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Compare NBIX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NBIX
Neurocrine Biosciences Inc
|
114.48 | 11.70B | 2.24B | 385.90M | 440.10M | 3.73 |
|
ZTS
Zoetis Inc
|
170.53 | 75.15B | 9.26B | 2.49B | 2.30B | 5.47 |
|
HLN
Haleon Plc Adr
|
10.58 | 47.71B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.84 | 47.70B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.00 | 18.75B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
131.28 | 13.96B | 612.78M | -86.37M | -62.91M | -0.87 |
Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-11-25 | Initiated | Deutsche Bank | Hold |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Aug-29-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Apr-24-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-13-23 | Resumed | Citigroup | Neutral |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Oct-24-23 | Resumed | Cantor Fitzgerald | Overweight |
| Aug-21-23 | Reiterated | Mizuho | Neutral |
| Jul-24-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Jul-06-23 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
| May-04-23 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-30-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Mar-03-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-03-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-14-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-11-22 | Initiated | UBS | Buy |
| Sep-26-22 | Initiated | Wells Fargo | Equal Weight |
| Jun-06-22 | Resumed | Jefferies | Buy |
| Mar-03-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Feb-25-22 | Upgrade | Goldman | Neutral → Buy |
| Jan-18-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-19-21 | Initiated | BMO Capital Markets | Underperform |
| Nov-17-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-14-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-23-21 | Resumed | Needham | Hold |
| Aug-06-21 | Downgrade | Canaccord Genuity | Buy → Hold |
| May-18-21 | Resumed | Goldman | Neutral |
| May-06-21 | Upgrade | Barclays | Equal Weight → Overweight |
| Feb-02-21 | Initiated | Raymond James | Outperform |
| Sep-30-20 | Initiated | The Benchmark Company | Hold |
| Aug-04-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-29-20 | Downgrade | Goldman | Buy → Neutral |
| Jun-09-20 | Initiated | Wedbush | Outperform |
| Mar-06-20 | Initiated | Citigroup | Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-24-20 | Initiated | William Blair | Outperform |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Feb-05-20 | Reiterated | H.C. Wainwright | Buy |
| Dec-13-19 | Downgrade | Credit Suisse | Outperform → Neutral |
| Aug-07-19 | Initiated | RBC Capital Mkts | Outperform |
| Jul-16-19 | Initiated | Oppenheimer | Outperform |
| Jun-05-19 | Initiated | Guggenheim | Neutral |
| May-21-19 | Initiated | Credit Suisse | Outperform |
| Apr-22-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Feb-06-19 | Reiterated | BofA/Merrill | Buy |
| Jan-23-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-13-18 | Initiated | Goldman | Buy |
| Nov-21-18 | Initiated | Canaccord Genuity | Buy |
View All
Neurocrine Biosciences Inc Stock (NBIX) Latest News
Why Neurocrine Biosciences Inc. (NBIX) Crashed Last Week - MSN
Fjarde AP Fonden Fourth Swedish National Pension Fund Has $7.59 Million Stock Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Illumine Investment Management LLC Invests $1.30 Million in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
GW&K Investment Management LLC Grows Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Los Angeles Capital Management LLC Has $70 Million Stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Neurocrine Biosciences (NasdaqGS:NBIX) Highlights INGREZZA's Positive Phase 4 Study Results - Simply Wall St
Neurocrine Biosciences, Inc. to Host Earnings Call - ACCESS Newswire
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Purchased by Peloton Wealth Strategists - MarketBeat
Phase IV Ingrezza data move focus from sales outlook - The Pharma Letter
NBIXNeurocrine Biosciences Inc Latest Stock News & Market Updates - StockTitan
Blackhawk Capital Partners LLC. Takes Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
C WorldWide Group Holding A S Boosts Stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Impax Asset Management Group plc Acquires 176,599 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Neurocrine's Phase 4 Study Shows INGREZZA Improves Quality Of Life For Tardive Dyskinesia Patients - Nasdaq
Neurocrine Biosciences Reports Patient-Reported Outcome Data from KINECT-PRO™ Study for INGREZZA® (valbenazine) Capsules in Tardive Dyskinesia: Significant and Clinically Meaningful Improvements in Functionality and Quality of Life Measures - PR Newswire
Endometriosis Market Predicted to See Upsurge Through 2034, - openPR
Neurocrine Biosciences (NASDAQ:NBIX) Receives Buy Rating from HC Wainwright - MarketBeat
Neurocrine Biosciences to Present at Upcoming Investor Conferences in March - PR Newswire
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Hussman Strategic Advisors Inc. - MarketBeat
Endometriosis Pipeline Drugs Analysis Report: FDA Approvals, - openPR
Neurocrine Biosciences authorizes $500M share repurchase program - MSN
Q3 EPS Forecast for Neurocrine Biosciences Cut by Analyst - MarketBeat
Vontobel Holding Ltd. Sells 6,148 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Is Neurocrine Biosciences (NBIX) One of the Best Fast Growth Stock to Buy Right Now? - Insider Monkey
Shareholders Can Be Confident That Neurocrine Biosciences' (NASDAQ:NBIX) Earnings Are High Quality - Simply Wall St
Neurocrine Biosciences' (NASDAQ:NBIX) Performance Is Even Better Than Its Earnings Suggest - Yahoo Finance
DSM Capital Partners LLC Has $127.30 Million Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Neurocrine Biosciences, Inc. authorizes a Buyback Plan. -February 20, 2025 - Marketscreener.com
Neurocrine Biosciences Board Of Directors Authorizes $500 Million Share Repurchase Program - Marketscreener.com
Assessing Neurocrine Biosciences: Insights From 15 Financial Analysts - Benzinga
Huntington's Disease Market Growth to Accelerate in Forecast - openPR
Neurocrine Biosciences sets $500M share buyback plan By Investing.com - Investing.com South Africa
Neurocrine Biosciences sets $500M share buyback plan - Investing.com India
Neurocrine Biosciences Approves $500 Million Share Repurchase Program -February 21, 2025 at 08:19 am EST - Marketscreener.com
Neurocrine Board Authorizes Share Repurchase ProgramQuick Facts - Nasdaq
Neurocrine Biosciences (NBIX) Announces $500M Share Buyback - StreetInsider.com
Neurocrine Biosciences Board of Directors Authorizes $500 Million Share Repurchase Program - PR Newswire
Leerink Partnrs Issues Optimistic Outlook for NBIX Earnings - MarketBeat
Rice Hall James & Associates LLC Sells 6,785 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Neurocrine Biosciences (NASDAQ:NBIX) Downgraded to Buy Rating by StockNews.com - MarketBeat
AlphaCentric Advisors LLC Sells 18,816 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Ieq Capital LLC Increases Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Van ECK Associates Corp Buys 9,824 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
New York State Teachers Retirement System Cuts Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Matt Abernethy Sells 2,558 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Stock - MarketBeat
Neurocrine (NBIX): Among Top Insider Stock Buys And Sells In January - Insider Monkey
Neurocrine Biosciences chief legal officer sells $107,727 in stock - MSN
Neurocrine Biosciences' chief corporate affairs officer sells shares worth $208,387 - MSN
Neurocrine Biosciences CFO Matt Abernethy sells $115,908 in stock - MSN
Neurocrine Biosciences' SWOT analysis: navigating growth amid market shifts By Investing.com - Investing.com Nigeria
Neurocrine Biosciences' SWOT analysis: navigating growth amid market shifts - Investing.com
Neurocrine Biosciences Inc Stock (NBIX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Neurocrine Biosciences Inc Stock (NBIX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Cooke Julie | Chief Human Resources Officer |
Feb 13 '25 |
Sale |
116.78 |
1,551 |
181,129 |
19,544 |
| GORMAN KEVIN CHARLES | Director |
Feb 13 '25 |
Option Exercise |
0.00 |
10,979 |
0 |
527,221 |
| GORMAN KEVIN CHARLES | Director |
Feb 13 '25 |
Sale |
116.69 |
5,844 |
681,914 |
521,618 |
| SHERWIN STEPHEN A | Director |
Feb 13 '25 |
Sale |
116.69 |
13,831 |
1,613,923 |
10,673 |
| ROBERTS EIRY | Chief Medical Officer |
Feb 13 '25 |
Option Exercise |
0.00 |
4,605 |
0 |
36,140 |
| ROBERTS EIRY | Chief Medical Officer |
Feb 13 '25 |
Sale |
116.85 |
1,718 |
200,742 |
34,252 |
| ROBERTS EIRY | Chief Medical Officer |
Feb 14 '25 |
Sale |
115.04 |
500 |
57,521 |
35,640 |
| Onyia Jude | Chief Scientific Officer |
Feb 13 '25 |
Option Exercise |
0.00 |
5,407 |
0 |
19,536 |
| Onyia Jude | Chief Scientific Officer |
Feb 13 '25 |
Sale |
116.79 |
2,879 |
336,239 |
16,846 |
| Lippoldt Darin | Chief Legal Officer |
Feb 13 '25 |
Option Exercise |
0.00 |
4,100 |
0 |
44,491 |
1.08%
0.64%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):